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Abstract 
Purpose: Type 2 diabetes (T2D) has been associated with depressive symptoms, but the causal 
direction of this association and the underlying mechanisms, such as increased glucose levels, 
remain unclear. We used instrumental-variable regression with a genetic instrument (Mendelian 
randomization) to examine a causal role of increased glucose concentrations in the development 
of depressive symptoms. Methods: Data were from the population-based Cardiovascular Risk in 
Young Finns Study (n = 1217). Depressive symptoms were assessed in 2012 using a modified 
Beck Depression Inventory (BDI-I). Fasting glucose was measured concurrently with depressive 
symptoms. A genetic risk score for fasting glucose (with 35 single nucleotide polymorphisms) 
was used as an instrumental variable for glucose. Results: Glucose was not associated with 
depressive symptoms in the standard linear regression (B = −0.04, 95% CI [–0.12, 0.04], p = .34), 
but the instrumental-variable regression showed an inverse association between glucose and 
depressive symptoms (B = –0.43, 95% CI [–0.79, –0.07], p = .020). The difference between the 
estimates of standard linear regression and instrumental-variable regression was significant (p = 
.026). Conclusions: Our results suggest that the association between T2D and depressive 
symptoms is unlikely to be caused by increased glucose concentrations. It seems possible that 
T2D might be linked to depressive symptoms due to low glucose levels. 
Keywords: depressive symptoms, fasting glucose, hyperglycemia, instrumental-variable 
regression, Mendelian randomization, type 2 diabetes (T2D) 
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Two recent meta-analyses of longitudinal studies [1–2] showed that people with type 2 
diabetes (T2D) have a 15-24% higher risk of developing depressive symptoms than those without 
T2D. It is, however, unclear whether this association is due to the causal effects of 
pathophysiological processes underlying diabetes [3]. Gaining this knowledge is important as it 
will have implications for prevention and treatment of these two conditions. 
Increased glucose associated with T2D has been investigated as one of the mechanisms 
linking T2D to depressive symptoms, but the reported results are inconsistent [4–10]. While some 
studies [4, 6] showed a positive association between hyperglycemia and depressive symptoms, 
others [9–10] suggested that increased glucose may not contribute to depressive symptoms, but 
rather, that depressive symptoms in T2D may reflect psychosocial stress associated with being 
diagnosed with T2D, and the burden of coping with T2D and its complications. One study [8] 
reported an increased risk of depressive symptoms in individuals with very high and very low 
fasting blood glucose concentrations and some investigations [5, 7] suggested a negative 
direction of the association. 
Determining the role of increased glucose in the development of depressive symptoms has 
been hampered by methodological limitations of observational data. More advanced methods 
could improve causal inference. Instrumental-variable regression with a genetic instrument 
(Mendelian randomization) is a statistical method that can reduce the effects of confounding and 
reverse causality by using genetic variants as instruments for the exposure of interest, such as 
glucose levels. Due to the random allocation of alleles during gamete formation, genetic variants 
are generally independent of any of the environmental factors that typically confound 
associations between exposures and disease outcomes in non-experimental studies. And as 
people’s genotypes are determined at conception, genetic variants precede health-related 
outcomes. Thus, instrumental-variable regression with genetic variants as instruments can 
FASTING GLUCOSE AND THE RISK OF DEPRESSIVE SYMPTOMS  5 
strengthen causal inference by providing estimates that are less likely to be affected by 
confounding and reverse causality than the estimates derived from conventional multiple 
regression [11–13]. The assumptions underlying instrumental-variable regression are depicted 
with more detail in Figure 1. 
 
------------------------------------------------------------ 
Insert Figure 1 here 
  ------------------------------------------------------------ 
 
Whereas conventional multiple regression examines how the outcome is related to the total 
variation in the risk factor across individuals, instrumental-variable regression is based only on 
the proportion of variation in the risk factor that is associated with the genetic variants used as the 
instrument for the risk factor. If the estimates of conventional multiple regression are biased by 
confounding or reverse causality, one would expect these estimates to differ from the estimates of 
instrumental-variable regression. If, on the other hand, the estimates derived from conventional 
regression do not differ significantly from the estimates of instrumental-variable regression, the 
risk factor can be assumed to be exogenous, in which case the estimates of the conventional 
regression model are preferable because they are more efficient, that is, more precise [14]. 
In this study, we implemented instrumental-variable regression with a genetic risk score for 
fasting glucose used as a proxy for fasting glucose to test whether increased glucose is causally 
associated with depressive symptoms. 
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Methods 
Participants 
The participants were from the Cardiovascular Risk in Young Finns Study, an ongoing, 
population-based prospective study examining cardiovascular risk factors in Finland [15–16]. 
The study has been conducted in all Finnish cities with a medical school (Helsinki, Kuopio, Oulu, 
Tampere, and Turku) and their rural surroundings. In total, 4320 healthy white Finnish children 
and adolescents aged 3, 6, 9, 12, 15, and 18 years were randomly selected using their unique 
personal identification numbers. Of these individuals, 3596 (83.2%) participated at the baseline 
study in 1980. Since that time, eight follow-up studies have been performed in: 1983, 1986, 1989, 
1992, 1997, 2001, 2007, and 2012. In the latest data collection phase, there were 2063 
participants (45% men). So far, 104 individuals have died and 1429 individuals have dropped out 
[17]. The study was approved by the local ethics committees. All the participants gave their 
written informed consent. 
The present cross-sectional study was based on data from the 2012 follow-up. Of the 2063 
individuals, 796 (38.6%) had some missing information on the study variables. People with the 
diagnosis of type 1 diabetes (T1D; n = 7) and T2D (n = 43) were excluded. Thus, the final sample 
consisted of 1217 participants. 
Measures 
Depressive symptoms in 2012 were self-rated with a modified version of the Beck 
Depression Inventory-I (BDI-I) [18], which was translated into Finnish and adopted for use in the 
Cardiovascular Risk in Young Finns Study [19–20]. The original version of the measure has 21 
items with four alternative response statements in each item (0 indicating absence and 1−3 
indicating increasing levels in the severity of depressive symptoms). In the modified version, the 
items are the second mildest statements of the BDI-I items, selected because they were suggested 
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to capture a wider variation in depressive symptoms in the general population compared with the 
original version of the measure [21]. The participants were asked to rate each of the 21 items on a 
5-point scale ranging from totally disagree (1) to totally agree (5). We calculated depressive 
symptoms’ severity score for each participant as the mean score of responses instead of 
classifying the participants into depressive symptoms’ groups. This was done due to two reasons: 
first, there have been no standardized cut-off points for the modified BDI-I and data-driven cut-
off points create a difficulty to compare results across different studies [22], and second, 
categorization of continuous variables may be associated with a loss of statistical power and an 
imprecise estimation [22]. The scale reliability (Cronbach’s α) was .92. The modified BDI-I has 
been shown to correlate with R = .77 (p < .001) with the BDI-II which is a tool to screen for 
clinical depression [21]. The validity of the modified BDI-I is also supported by previous studies 
that have associated this instrument with psychosocial characteristics known to be associated 
with depressive symptoms, such as negative emotionality and low sociability [23], fatigability 
and sentimentality [24], and hostility and low social support [25]. Additionally, the measure has 
been shown to be a valid predictor of risk factors for cardiovascular disease, such as preclinical 
atherosclerosis [26] and the metabolic syndrome [27]. 
Fasting serum glucose concentration was measured in 2012 with the enzymatic hexokinase 
method (Glucose reagent, Beckman Coulter Biomedical) using an AU400 instrument (Olympus, 
Japan). Body mass index (BMI) in 2012 was calculated as weight (kg) / height2 (m2). Height was 
measured with a wall-stated stadiometer and weight with Seca scales. Physical activity in 2012 
was measured with a questionnaire consisting of five items concerning: the intensity of physical 
activity, frequency of vigorous physical activity, hours spent on vigorous physical activity, 
average duration of a physical activity session, and participation in organized physical activity. 
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The scale was previously described in detail by Telama et al. [28]. Overall physical activity was 
calculated as the sum score of responses. 
Both BMI and physical activity have been associated with T2D and depressive symptoms 
[3]. Therefore, the potential confounding effects of the two variables, together with the effects of 
sex and age, were controlled in our analyses. 
The genome wide single nucleotide polymorphism (SNP) analyses (GWAS) for the 
Cardiovascular Risk in Young Finns Study participants were performed in 2009 by using the 
670K Illumina platform (Sanger Institute, UK). Variation in over 670000 known SNPs was 
measured from 2627 participants. Genotype imputation was performed using SHAPEIT [29] and 
IMPUTE2 software [30], and the 1000G Phase I Integrated Release Version 3 Haplotypes [31] as 
a reference panel. A weighted genetic risk score comprising 35 previously published risk SNPs 
for fasting glucose [32–34] was calculated as the sum of genotyped risk alleles or imputed allele 
dosages carried by an individual, each multiplied by the effect size (the natural log of the odds 
ratios) using R software version 2.15.3. Details of these SNPs are provided in Supplementary 
Table 1. We used a weighted instead of an unweighted genetic risk score as the use of a weighted 
allele score has been shown to increase statistical power [35]. 
Statistical Analysis 
The statistical analysis was performed using Stata/SE 13 software. The association between 
glucose and depressive symptoms was examined with standard linear regression and 
instrumental-variable regression (the generalized method of moments, GMM) [36] controlling for 
sex, age, BMI and physical activity, and allowing for heteroscedasticity of the error term by using 
“wmatrix (robust)” option [36]. The results of the standard linear regression and the instrumental-
variable regression were compared implementing the difference-in-Sargan test (the C statistic) 
[36]. The associations between the genetic risk score and the study covariates were tested with 
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linear and binary logistic regression. The strength of the association of the genetic risk score with 
glucose was evaluated on the basis of the F-statistic from the first-stage regression analysis. The 
F-value greater than 10 is commonly used as evidence that an instrument is sufficiently strong 
[37]. The attrition analysis was carried out with the two-sample t-test and the chi-square test. 
Additionally, the main analysis was repeated in the imputed data for all of those 
participants of the Young Finns Study who had information on the genetic risk score for fasting 
glucose and who did not have the diagnosis of T1D or T2D in 2012 (n = 2527). Multiple imputed 
values were generated for the missing data from the variables used in the analysis with Stata 
imputation by chained equations (ice) [38]. Fifty datasets were randomly selected and then 
analyzed using “mi estimate” option and “mibeta” command. 
Results 
Individuals included in the study sample (n = 1217) and those who were lost due to attrition 
did not differ in age (42.91 vs. 42.61, p = .19), the genetic risk score for fasting glucose (−0.04 
vs. −0.001, p = .41), and physical activity (9.05 vs. 8.93, p = .22). The groups differed, however, 
in respect of depressive symptoms (2.04 vs. 2.22, p < .001), glucose levels (5.26 vs. 5.42, p < 
.001), and BMI (26.07 vs. 26.94, p < .001). Also, more men than women dropped out (45.4% vs. 
33.9%, p < .001). Table 1 summarizes the characteristics of the study participants. 
 
------------------------------------------------------------ 
Insert Table 1 here 
  ------------------------------------------------------------ 
 
Table 2 shows the associations between the genetic risk score and the study covariates. The 
genetic risk score was not associated with sex, age, BMI, or physical activity. There was an 
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association of the genetic risk score with glucose (B = 0.09, 95% CI [0.07, 0.12], p < .001) and 
depressive symptoms (B = –0.04 95% CI [–0.07, –0.005], p = .025). The F-value of the 
association of the genetic risk score with glucose while adjusting for sex, age, BMI, and physical 
activity indicated that the genetic risk score was a sufficiently strong genetic instrument for this 
variable (F = 69.72, R2 = 22.35%). 
 
------------------------------------------------------------ 
Insert Table 2 here 
  ------------------------------------------------------------ 
 
The results of the standard linear regression and the instrumental-variable regression with 
their comparison are shown in Table 3. In the standard linear regression analysis, depressive 
symptoms were not associated with glucose (B = −0.04, 95% CI [–0.12, 0.04], p = .34) when 
controlling for sex, age, BMI, and physical activity. In the instrumental-variable regression, 
however, the effect of glucose on depressive symptoms was statistically significant after 
adjustment for those four covariates (B = –0.43, 95% CI [–0.79, –0.07], p = .020). The difference 
between the estimates of standard linear regression and instrumental-variable regression models 
was also significant (p = .026). 
 
------------------------------------------------------------ 
Insert Table 3 here 
  ------------------------------------------------------------ 
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The results of the analysis performed in the data with imputed values are presented in 
Supplementary Table 2 and Supplementary Table 3. The assumptions underlying instrumental-
variable regression were met. The strength of the association between the genetic risk score and 
glucose was sufficient (F = 98.20; R2 = 21.83%). The results of the standard-linear regression 
showed that glucose was not associated with depressive symptoms after controlling for sex, age, 
BMI, and physical activity (B = −0.02, 95% CI [–0.11, 0.06], p = .58). In the fully adjusted 
instrumental-variable regression model, the association between glucose and depressive 
symptoms was, however, statistically significant (B = –0.42, 95% CI [–0.76, –0.08], p = .015). 
The difference between the estimates of standard linear regression and instrumental-variable 
regression models were significant in 48 out of 50 imputed datasets (ps < .05). Overall, these 
additional tests suggest that it is unlikely that the results derived from the analysis of the 
incomplete data could be biased by the attrition. 
Discussion 
To our knowledge, this is the first study in which the Mendelian randomization approach 
was applied to examine a causal role of increased glucose in the development of depressive 
symptoms. The results of the standard linear regression showed that glucose is not associated 
with depressive symptoms when controlling for sex, age, BMI, and physical activity. The 
instrumental-variable regression showed a negative association between glucose and depressive 
symptoms in the fully adjusted model. The difference between the estimates derived from the two 
methods was significant. Thus, these results do not support increased glucose levels to be a causal 
risk factor for depressive symptoms in people with T2D. The association between T2D and 
depressive symptoms might be due to hypoglycemia. 
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Our finding is in line with the results of two observational studies [5, 7], which suggested 
that the association between hyperglycemia and depressive symptoms may be negative. Insulin 
resistance related to T2D has also been inversely associated with the risk of depressive symptoms 
(together with depression) [39–40], although not in all studies [41–43]. The present study, 
however, advances previous investigations about the association between glucose levels and 
depressive symptoms [4–10] by utilizing genetic information in instrumental-variable regression 
to reduce bias caused by confounding and reverse causation, and thus to strengthen causal 
inference regarding this association. Our results support the conclusion of a recent literature 
review [3] of observational studies that the pathophysiology of T2D, such as chronic 
hyperglycemia, is unlikely to contribute to depressive symptoms. Our results suggest that the 
association between T2D and depressive symptoms could be mediated by low glucose 
concentrations. There is some evidence that hypoglycemia, affecting approximately 23% of 
individuals with T2D diagnosis [44], is associated with an increased risk of depressive symptoms 
in this group of patients [44–45]. 
One of the assumptions underlying instrumental-variable regression is that the genetic 
variants used as an instrumental variable should influence the outcome only through the exposure 
of interest [13]. In practice, this methodological assumption is untestable [46–47] and it can be 
violated by, for instance, population stratification and pleiotropy [13]. It is unlikely that our 
results were affected by population stratification as the study sample consisted of only native 
Finnish people. Pleiotropic genetic effects might violate the assumption if the genetic instrument 
directly influenced the outcome or if the association between the genetic instrument and the 
outcome was mediated by other factors besides the exposure of interest. It is possible that the 35-
SNP genetic risk score for fasting glucose influences depressive symptoms via other pathways 
besides glucose. If that was proven to be true, the above assumption underlying instrumental-
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variable regression would be violated, and thus the causal link between glucose and depressive 
symptoms would be overestimated. 
Depressive symptoms were self-reported with a modified version of the BDI-I which is not 
a measure of clinical depression but a measure of mild depressive symptoms. Glucose 
concentrations might be related to depressive symptoms differently than to depression [4]. Thus, 
our results may not be applicable to clinically diagnosed depression. 
However, depressive symptoms may also be considered as an indicator of an early stage of 
clinical depression. Subthreshold depressive symptoms have been shown to predict an increased 
risk of developing major depressive disorder later on [48]. Decreased glucose could thereby 
increase the risk of clinical depression by contributing to the progression of depressive 
symptoms. 
A relatively large population-based sample provided a methodological strength to our 
study. The inclusion of a young cohort (an age range of 35 to 50 years) can be seen as both a 
strength and a limitation. Due to a paucity of studies in the field of T2D and depressive 
symptoms conducted on younger populations, our study makes a unique contribution in this 
respect. However, the age range may have underestimated the role of glucose in the development 
of depressive symptoms in older individuals, given that the incidence of T2D begins to increase 
rapidly after midlife [49]. 
In conclusion, our results provide evidence suggesting that it is unlikely that the association 
between T2D and depressive symptoms is caused by increased glucose concentrations. 
Furthermore, it seems possible that T2D might be linked to depressive symptoms due to low 
glucose levels. Considering the methodological limitations of instrumental-variable regression, 
this finding should be interpreted carefully and needs to be replicated in other studies. In addition, 
we suggest that in further studies more attention could be given to possible mediating factors of 
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the association between the genetic risk score for fasting glucose and depressive symptoms. 
Moreover, future research needs to focus on testing the association of glucose with clinically 
diagnosed depression. Additional studies examining this association in older populations, among 
whom T2D is more prevalent, are also of value. Finally, the present results suggest that the effect 
of depressive symptoms on the development of T2D requires further examination, especially 
using genetic data. 
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Figure 1. Assumptions underlying instrumental-variable regression. Genetic variants can be used as 
an instrumental variable for a modifiable exposure if they are: 1) associated with the exposure of 
interest; 2) independent of any possible factors confounding the association between the exposure 
and the outcome; and 3) associated with the outcome only through the exposure of interest. 
1 
 
Table 1 
Descriptive Statistics (n = 1217) 
Study variables n (%) M (SD) Range 
    
Sex 1217   
   Men 500 (41.1)    
   Women 717 (58.9)   
Age (years)  42.91 (5.00) 35.00–50.00 
Depressive symptoms  2.04 (0.62) 1.00–4.43 
35-SNP genetic risk score  −0.04 (1.01) −3.28–3.01 
Glucose (mmol/L)  5.26 (0.48) 3.14–6.84 
BMI (kg/m2)  26.07 (4.67) 17.01–58.47 
Physical activity    9.05 (1.85) 5.00–15.00 
    
Abbreviations: M, mean; n, number of participants; SD, standard deviation. 
The 35-SNP genetic risk score expressed in standard score. 
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Table 2 
Associations Between the 35-SNP Genetic Risk Score of Fasting Glucose and the Study 
Covariates (n = 1217) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: B, unstandardized linear regression coefficient; CI, confidence interval; R2, fraction of explained variance (%). 
 
 
 
 
 
 
 
 
 
 
 Genetic risk score 
Outcome B  95% CI R2 (%) p-value 
     
Sex 0.002 [–0.11, 0.12] 0.00 .97 
Age 0.03 [–0.25, 0.31] 0.00 .83 
BMI –0.14 [–0.40, 0.12] 0.09 .30 
Physical activity −0.08 [−0.18, 0.02] 0.19 .13 
Glucose 0.09 [0.07, 0.12]    3.84 < .001 
Depressive symptoms –0.04 [–0.07, –0.005] 0.41 .025 
     
3 
Table 3 
Standard Linear Regression and Instrumental-Variable Regression Predicting Depressive 
Symptoms With Glucose (n = 1217) 
 Standard linear regression  Instrumental-variable regressiona   
Predictors B 95% CI p-value  B 95% CI p-value 
 
 
p-value for a difference 
between the modelsb 
          
Glucose −0.04 [–0.12, 0.04] .34  –0.43 [–0.79, –0.07] .020  .026 
          
Abbreviations: B, unstandardized linear regression coefficient; CI, confidence interval. 
Models adjusted for sex, age, BMI, and physical activity. 
aIn the instrumental-variable regression, the 35-SNP genetic risk score of fasting glucose was used as an instrumental variable for glucose. 
bDifference-in-Sargan test. 
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Supplementary Table 1 
Details of the 35 SNPs Used to Calculate the Genetic Risk Score for Fasting Glucose 
SNP Nearby gene(s)a Minor allele frequencyb 
   
rs560887 G6PC2 .31 
rs10830963 MTNR1B .36 
rs4607517 GCK .11 
rs2191349 DGKB-TMEM195 .46 
rs780094 GCKR .36 
rs10811661 CDKN2B .15 
rs3736594 MRPL33 .33 
rs4869272 PCSK1 .33 
rs983309 PPP1R3B .18 
rs11708067 ADCY5 .18 
rs1371614 DPSYL5 .23 
rs6943153 GRB10 .49 
rs11603334 ARAP1 .26 
rs6048205 FOXA2 .05 
rs16913693 IKBKAP .02 
rs2293941 PDX1 .26 
rs7944584 MADD .19 
rs3829109 DNLZ .36 
rs3783347 WARS .19 
rs13179048 PCSK1 .33 
rs13266634 SLC30A8 .38 
rs2302593 GIPR .48 
rs9368222 CDKAL1 .34 
rs7034200 GLIS3 .50 
rs10747083 P2RX2 .38 
rs174550 FADS1 .40 
rs17762454 RREB1 .29 
rs7708285 ZBED3 .22 
rs6072275 TOP1 .24 
rs7651090 IGF2BP2 .31 
rs576674 KL .10 
rs7903146 TCF7L2 .19 
rs1483121 OR4S1 .12 
rs2657879 GLS2 .19 
rs11715915 AMT .44 
   
aAll information derived from Dupuis et al. [32], Manning et al. [33], and Scott et al. [34]. 
bData calculated based on the Cardiovascular Risk in Young Finns Study sample. 
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Supplementary Table 2 
Associations Between the 35-SNP Genetic Risk Score of Fasting Glucose and the Study Covariates 
in the Data With Imputed Values (n = 2527) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: B, unstandardized linear regression coefficient; CI, confidence interval; R2, fraction of explained variance (%). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Genetic risk score 
Outcome B  95% CI R2 (%) p-value 
     
Sex –0.02 [–0.10, 0.06] 0.01 .63 
Age –0.17 [–0.36, 0.03] 0.12 .088 
BMI –0.20 [–0.42, 0.01] 0.20 .068 
Physical activity −0.03 [−0.12, 0.06] 0.05 .53 
Glucose 0.09 [0.07, 0.11]    3.54 < .001 
Depressive symptoms –0.04 [–0.08, –0.01] 0.48 .012 
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Supplementary Table 3 
Standard Linear Regression and Instrumental-Variable Regression Predicting Depressive 
Symptoms With Glucose in the Data With Imputed Values (n = 2527) 
 Standard linear regression  Instrumental-variable regression 
Predictors B 95% CI p-value  B 95% CI p-value 
        
Glucose −0.02 [–0.11, 0.06] .58  –0.42 [–0.76, –0.08] .015 
        
Abbreviations: B, unstandardized linear regression coefficient; CI, confidence interval. 
Models adjusted for sex, age, BMI, and physical activity. 
In the instrumental-variable regression, the 35-SNP genetic risk score of fasting glucose was used as an instrumental variable for glucose. 
 
